Continuous HAART Associated With Decreased Bone Mineral Density, SMART Substudy Finds
In one of ICAAC/IDSA 2008's most talked-about studies, a SMART substudy suggests that participants who remained on HAART continuously experienced a significantly greater reduction in bone marrow density than patients on intermittent therapy. (An interview with Birgit Grund, Ph.D.)
Continuous HAART Associated With Decreased Bone Mineral Density, SMART Substudy Finds (Posted Nov. 3, 2008)
In one of ICAAC/IDSA 2008's most talked-about studies, a SMART substudy suggests that participants who remained on HAART continuously experienced a significantly greater reduction in bone marrow density than patients on intermittent therapy. (An interview with Birgit Grund, Ph.D.)
Hospitalization Risk Similar Between HAART Responders and Nonresponders for 90 Days After Starting Therapy (Posted Oct. 28, 2008)
The benefits of HAART initiation -- at least in terms of preventing or ameliorating illnesses that require hospitalization -- may not manifest themselves for up to three months, according to a sizeable study by Johns Hopkins University researchers. Women were more likely to be hospitalized than men, and choice of HAART regimen appeared to have no impact. (An interview with Stephen Berry, M.D.)
Diabetes Risk Appears Lower for HIV-Positive Patients Than Negative Patients (Posted Oct. 27, 2008)
A large, ongoing study of U.S. military veterans also suggests that the usual risk factors for diabetes, not HIV itself, are the main drivers of diabetes in HIV-positive people. (An interview with Adeel A. Butt, M.D.)
HAART Use Improves Hepatitis B Vaccine Response, Even at High CD4 Counts (Posted Oct. 27, 2008)
HIV-positive patients are approximately twice as likely to respond to hepatitis B vaccination if they are receiving antiretroviral therapy, regardless of their CD4+ cell count at the time of vaccination, according to a study by researchers with the U.S. military. (An interview with Michael Landrum, M.D.)
Patients on Tenofovir/Emtricitabine May Face Higher Bone Risk From Vitamin D Insufficiency (Posted Oct. 27, 2008)
A small study finds that, although vitamin D insufficiency is quite common among HIV-positive people, it may be a particular risk for patients receiving tenofovir/emtricitabine: These patients appear especially likely to have elevated parathyroid hormone levels, which has been associated with bone problems. (An interview with Kate Childs, M.D.)
Trend Toward Fewer AIDS-Defining Conditions Among Patients Receiving Raltegravir vs. Placebo (Posted Oct. 26, 2008)
A new examination of 48-week BENCHMRK data found a nearly twofold reduction in AIDS-defining events among patients on raltegravir, but the findings failed to reach statistical significance. Intriguingly, greater resistance did not appear to be a predictor of AIDS-defining events. (An interview with Joseph Eron Jr., M.D.)
The Body PRO's coverage of The 48th Annual ICAAC/IDSA 46th Annual Meeting will include a wide array of individual presentations and symposia, as well as summaries of some of the hottest topics in HIV research.
For more information on The 48th Annual ICAAC/IDSA 46th Annual Meeting, please visit the conference's Web site. You may also view the conference program online.
Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.
E-Mail
Glossary
Share
